What peri‑operative chemotherapy and immunotherapy regimen should be used for a surgical candidate with early‑stage non‑small cell lung cancer?

Perioperative Chemoimmunotherapy for Early-Stage NSCLC

For surgical candidates with early-stage NSCLC (stage II-III or tumors ≥4 cm), use perioperative chemoimmunotherapy consisting of neoadjuvant checkpoint inhibitor plus platinum-based chemotherapy followed by surgery and adjuvant checkpoint inhibitor therapy. 1

Three Category 1 Regimen Options

All three regimens below have equivalent Category 1 recommendations based on phase III data 1:

1. Nivolumab + platinum-doublet chemotherapy (neoadjuvant) → surgery → nivolumab alone (adjuvant) for patients without EGFR mutations or ALK rearrangements

2. Pembrolizumab + cisplatin-based chemotherapy (neoadjuvant) → surgery → pembrolizumab alone (adjuvant) - demonstrated 62.4% event-free survival at 24 months versus 40.6% with chemotherapy alone (HR 0.58, P<0.001) 2

3. Durvalumab + platinum-based chemotherapy (neoadjuvant) → surgery → durvalumab alone (adjuvant) for patients without EGFR mutations or ALK rearrangements

Patient Selection Algorithm

Candidates for perioperative immunotherapy:

• Stage II-III resectable NSCLC OR tumors ≥4 cm 1
• No EGFR exon 19 deletion/exon 21 L858R mutations (for most regimens)
• No ALK, RET, or ROS1 rearrangements (for most regimens)
• No active autoimmune disease or current immunosuppressive therapy 1
• PD-L1 status does NOT exclude patients - benefit seen across all PD-L1 levels, though higher expression trends toward greater benefit 1

Alternative approaches:

• Stage IB (≥3 cm) and stage II with EGFR mutations: Use adjuvant osimertinib after surgery 3
• ALK-positive disease: Use adjuvant alectinib after surgery 1
• Patients ineligible for immunotherapy: Neoadjuvant or adjuvant platinum-based chemotherapy alone 1

Critical Implementation Points

Do not switch immunotherapy agents mid-treatment - perioperative therapy should be given as a single continuous regimen 1. The exploratory suggestion that perioperative approaches may outperform neoadjuvant-only strategies lacks definitive evidence and has methodological concerns 1.

Mandatory surgical standards: Perform systematic intraoperative mediastinal and hilar lymph node sampling or dissection during all stage I-II NSCLC operations to ensure accurate staging and treatment decisions 3.

Pre-treatment requirements:

• Pathological mediastinal staging 4
• Molecular testing for EGFR, ALK, and PD-L1 status 1
• Multidisciplinary tumor board evaluation 4

Nuanced Considerations

The three perioperative regimens have never been directly compared head-to-head 1. Selection should be based on:

• Trial eligibility criteria matching your patient
• Local drug approvals and availability
• Specific contraindications (EGFR/ALK status varies by agent)
• Patient comorbidities and tolerance

Safety profile: Grade 3+ treatment-related adverse events occur in approximately 45% with immunotherapy versus 37% with chemotherapy alone, but this does not compromise surgical feasibility 2. Grade 5 events remain rare (1.0% vs 0.8%) 2.

Common Pitfalls to Avoid

• Do not exclude PD-L1 negative patients - they still derive benefit, albeit potentially less than PD-L1 positive patients 1
• Do not use checkpoint inhibitors in EGFR/ALK-driven tumors - these patients are less likely to benefit and have superior targeted therapy options 1
• Do not consider upfront surgery alone for stage III or N-positive disease - these patients particularly benefit from perioperative immunotherapy 4
• Stage II N0 disease may be considered for upfront surgery in selected cases, though perioperative therapy remains an option 4

The integration of immunotherapy into early-stage NSCLC represents a paradigm shift, with pathological complete response rates increasing from 4% to 18% and major pathological response from 11% to 30% 2, translating into meaningful survival improvements 3.